Related Experiment Video
Updated: Jun 14, 2025
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Decentralized Clinical Trials in Early Drug Development-A Framework Proposal
Diogo J Silva1, Blessie Elizabeth Nelson2, Jordi Rodon2
1Local Health Unity of Matosinhos - Hospital Pedro Hispano, Matosinhos, Portugal.
Abstract:
The COVID-19 pandemic has led to a rethinking of clinical trial design to maintain clinical research activity, with regulatory changes allowing for the wider implementation and development of decentralized design models. Evidence of the feasibility and benefits associated with a remote design comes mainly from observational studies or phase 2 and 3 clinical trials, in which implementation is easier with a better-established safety profile. Early drug development is a slow and expensive process in which accrual and safety are key aspects of success. Applying a decentralized model to phase 1 clinical trials could improve patient accrual by removing geographic barriers, improving patient population diversity, strengthening evidence for rare tumors, and reducing patients' financial and logistical burdens. However, safety monitoring, data quality, shipment, and administration of the investigational product are challenges to its implementation. Based on published data for decentralized clinical trials, we propose an exploratory framework of solutions to enable the conceptualization of a decentralized model for phase 1 clinical trials.
Insights
Decentralized clinical trials (DCTs) can enhance early drug development by improving patient access and diversity. This study proposes a framework to address safety and logistical challenges in phase 1 DCTs.
Area of Science:
- Clinical pharmacology and drug development
- Clinical trial methodology
- Regulatory science
Background:
- The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs).
- Existing evidence for DCT feasibility and benefits primarily comes from later-phase trials (Phase 2/3) and observational studies.
- Early drug development (Phase 1) faces unique challenges including patient accrual and safety monitoring.
Purpose of the Study:
- To explore the potential of decentralized models in Phase 1 clinical trials.
- To identify benefits of applying decentralized approaches to early drug development.
- To propose solutions for challenges hindering Phase 1 DCT implementation.
Main Methods:
- Review of published data on decentralized clinical trials.
- Analysis of feasibility and benefits in various trial phases.
- Development of an exploratory framework for Phase 1 DCTs.
Main Results:
- Decentralized Phase 1 trials can improve patient accrual by overcoming geographic barriers.
- DCTs can enhance patient population diversity, benefiting rare tumor research.
- Key challenges include safety monitoring, data integrity, product shipment, and administration.
Conclusions:
- Decentralized models offer significant advantages for Phase 1 clinical trials, including improved patient access and diversity.
- Addressing safety, data quality, and logistical challenges is crucial for successful Phase 1 DCT implementation.
- An exploratory framework is proposed to guide the conceptualization of decentralized Phase 1 trials.
Related Concept Videos
01:11Clinical Trials: Overview
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:28Preclinical Development: Overview
01:29Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
01:26Drug Discovery: Overview
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...